Ganitumab: Difference between revisions
Content deleted Content added
No edit summary |
Updating {{infobox_drug}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'Watchedfields') per Chem/infobox_drug validation (report errors or bugs) |
||
| Line 1: | Line 1: | ||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
|||
| verifiedrevid = 458275232 |
| verifiedrevid = 458275232 |
||
| type = mab |
| type = mab |
||
| Line 36: | Line 37: | ||
| C=6472 | H=10028 | N=1728 | O=2020 | S=42 |
| C=6472 | H=10028 | N=1728 | O=2020 | S=42 |
||
| molecular_weight = 145.7 kg/mol |
| molecular_weight = 145.7 kg/mol |
||
| ChemSpiderID_Ref = {{chemspidercite| |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = none |
| ChemSpiderID = none |
||
}} |
}} |
||
Revision as of 12:19, 11 August 2016
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF-1R |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6472H10028N1728O2020S42 |
| Molar mass | 145.7 kg/mol g·mol−1 |
  (what is this?) (verify) | |
Ganitumab a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1]
Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[2][3]
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |